Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Cholangiocellular and gallbladder carcinoma].

¹Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover. Kubicka.stefan@mh-hannover.de

Zeitschrift Fur Gastroenterologie

|May 12, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703].

ESMO open·2025

Same author

mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214).

ESMO open·2024

Same author

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.

ESMO open·2023

Same author

Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.

European journal of cancer (Oxford, England : 1990)·2021

Same author

Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.

Cancer treatment reviews·2017

Same author

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials.

Gastroenterology research and practice·2016

Bile duct and gallbladder cancers are diagnosed using imaging and endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP). Surgery offers the only cure, while chemotherapy shows moderate effectiveness, especially combination therapies.

Area of Science:

Oncology
Gastroenterology

Context:

Bile stones and chronic biliary inflammation are key risk factors for cholangiocarcinoma and gallbladder carcinoma.
Diagnosis involves ultrasonography, CT, MRI for intrahepatic and gallbladder cancers, and ERCP/MRCP for perihilar/distal cholangiocarcinomas.

Purpose:

To review the current understanding of risk factors, diagnosis, treatment options, and supportive care for gallbladder and bile duct carcinomas.

Summary:

Surgical resection is the only curative treatment. Chemotherapy, particularly gemcitabine/cisplatin combinations, shows moderate response rates (20-50%) in phase II studies.
There is no current indication for neoadjuvant or adjuvant chemotherapy outside clinical trials due to low incidence and lack of large-scale comparative studies.
Palliative chemotherapy is recommended for patients in good condition, while supportive endoscopic procedures (stenting, photodynamic therapy) improve quality of life by maintaining bile flow.

Related Experiment Videos

Impact:

Highlights the limited role of chemotherapy and the importance of surgical intervention and supportive endoscopic therapies.
Emphasizes the need for clinical studies to evaluate chemotherapy's impact on survival and quality of life for these rare cancers.
Provides guidance on patient selection for palliative chemotherapy based on general physical condition and tumor-associated symptoms.